RT Journal Article
SR Electronic
T1 The challenge of medication adherence to reduce cardiovascular risk in primary care: a mixed design multi-center study in underserved populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.30.23287988
DO 10.1101/2023.03.30.23287988
A1 Puschel, K
A1 Gonzalez, K
A1 Varas, J
A1 Sateler, J
A1 Aravena, H
A1 Greig, D
A1 Escalona, G
A1 Palominos, M
A1 Rioseco, A
A1 Cea, A
A1 Thompson, B
YR 2023
UL http://medrxiv.org/content/early/2023/03/31/2023.03.30.23287988.abstract
AB Background Cardiovascular disease is a leading cause of death in Latin America. Internationally, low medication adherence is associated with 15% to 40% of excess cardiovascular deaths. In Latin America, the magnitude of low medication adherence and the factors associated with it, are not well known, especially among socially vulnerable populations. The aim of this study is to estimate the magnitude and associated factors of low medication adherence in a socially vulnerable population with high cardiovascular risk in Chile.Methods The study is based on a mixed-methods design. It included a multicenter cross-sectional design of a randomly selected clinical population of 900 participants, and a qualitative design based on the analytical framework model, that included patients and health team members, from three primary care clinics in Chile.Results Only 24.6% from the 886 (out of 900) patients who completed the study had “high” medication adherence, 24.9% had “regular,” and 50.4% had “low” adherence. Depression was the main factor associated with regular and low adherence combined (OR: 2.12; 95%CI:1.55-2.89). Confusion and tiredness were identified as barriers for adherence. Main facilitators reported by patients included better understanding of the medications, and availability of reminders. Clearer information and family support were identified by team members as initiators for improving adherence.Conclusion Low medication adherence is highly prevalent among patients with high cardiovascular risk in a low-income population in Chile. Quantitatively, depression was a significant risk factor for regular and low adherence; qualitatively, confusion and tiredness were identified as barriers. Clearer information and family support are identified as potential facilitators.What is new?▪ Cardiovascular disease is a growing epidemic in Latin America▪ Low medication adherence is a significant risk factor for cardiovascular diseaseWhat are de clinical implications?▪ Low medication adherence is highly prevalent in socially vulnerable populations of high cardiovascular risk in Chile.▪ Depression increased the risk of low medication adherence by more than two times in high-risk populations and is associated with the perception of confusion and tiredness in this group of patients.▪ Primary care teams recognize the relevance of providing clearer information, reminder systems and developing family support strategies for improving medication adherence.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCllinicaltrials.gov Prococol Registration NCT05395806Funding StatementThis project is funded by the Chilean National Agency for Research and Development (ANID) (SA20I0001)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was reviewed and approved by the Institutional Review Boards at the Faculty of Medicine Pontificia Universidad Católica de Chile as well as Servicio de Salud Concepción and Servicio de Salud del Maule, Chile (CI200117003).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data referred to in the manuscript is availability. https://drive.google.com/drive/folders/1WC46ZQ5OP2QdRZ26lRGsTn4ojmInv7Pw